Showing results (11-20 of 18) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Brain Research|February 16, 2013
Curcumin aggravates CNS pathology in experimental systemic lupus erythematosusSean Foxley, Marta Zamora, Bradley Hack, et al.Frontiers in Immunology|April 13, 2023
Host-specific differences in top-expanded TCR clonotypes correlate with divergent outcomes of anti-PD-L1 treatment in responders versus non-respondersJessy John, Samantha M Y Chen, Rachel A Woolaver, et al.Biorxiv : the Preprint Server for Biology|February 6, 2026
PRDX6 Modulates Immune Checkpoint Inhibitor Response by Antagonizing Ferroptosis Induced By HDAC InhibitorsZeyu Liu, Jessy John, Nickolas Johnson, et al.International Journal of Molecular Sciences|November 27, 2024
Targeting Myeloid Cells in Head and Neck Squamous Cell Carcinoma: A Kinase Inhibitor Library Screening ApproachMohamed Y Zaky, Jessy John, Monika Vashisht, et al.Frontiers in Immunology|July 26, 2024
Differential tumor immune microenvironment coupled with tumor progression or tumor eradication in HPV-antigen expressing squamous cell carcinoma (SCC) modelsArpitha H Shivarudrappa, Jessy John, Monika Vashisht, et al.Frontiers in Immunology|November 4, 2022
Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumorsJessy John, Rachel A Woolaver, Vince Popolizio, et al.Journal of Experimental & Clinical Cancer Research : CR|April 3, 2022
Differential responses to immune checkpoint inhibitor dictated by pre-existing differential immune profiles in squamous cell carcinomas caused by same initial oncogenic driversSamantha M Y Chen, Vince Popolizio, Rachel A Woolaver, et al.Experimental Hematology & Oncology|June 10, 2026
Multifactorial effects of LGALS1 blockade sensitize tumors to immune checkpoint inhibitorJessy John, Mohammad A I Al-Hatamleh, Monika Vashisht, et al.Pageof 2